B cell-regulated immune responses in tumor models and cancer patients

OncoImmunology

Volumn 2, Issue 7, 2013, Pages

  Fremd, Carlo ^a   Schuetz, Florian ^a   Sohn, Christof ^a   Beckhove, Philipp ^b   Domschke, Christoph ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antitumor immunity; B cells; Regulatory B cells; T cells; Tregs; Tumor specific immune responses

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; FC RECEPTOR; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN KAPPA CHAIN; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; LYMPHOTOXIN ALPHA BETA; OCRELIZUMAB; OFATUMUMAB; PREDNISONE; RITUXIMAB; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VELTUZUMAB; VINCRISTINE;

ANTIGEN PRESENTING CELL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BREAST ADENOCARCINOMA; BREAST CARCINOMA; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD19+ B220+ CD25+ B LYMPHOCYTE; CD4+ CD25 HIGH FOXP3+ REGULATORY T LYMPHOCYTE; CD4+ CD25 HIGH REGULATORY T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; COLON CARCINOMA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; HUMAN; HUMORAL IMMUNE DEFICIENCY; LIVER CELL CARCINOMA; LUNG CANCER; LUNG METASTASIS; LYMPHOCYTE FUNCTION; LYMPHOMA; MELANOMA B16; MOLECULAR INTERACTION; NATURAL KILLER CELL; NONHUMAN; PROSTATE CARCINOMA; REGULATORY T LYMPHOCYTE; SKIN CARCINOGENESIS; T LYMPHOCYTE; THYMOMA; TUMOR IMMUNITY; TUMOR MODEL;

EID: 84886943750     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25443     Document Type: Article

References (93)

1. Thomas L. Discussion. In: Lawrence HS, ed. Cellular and Humoral Aspects of the Hypersensitive States. New York, NY: Hoeber-Harper, 1959:529-33.
2. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13:1-27; PMID:4921480
3. Cooper MD, Raymond DA, Peterson RD, South MA, Good RA. The functions of the thymus system and the bursa system in the chicken. J Exp Med 1966; 123:75- 102; PMID:5323079; http://dx.doi.org/10.1084/ jem.123.1.75
4. Ivanyi J, Lydyard PM.Delineation of chicken lymphocyte populations by specific anti-thymus and anti-bursa sera.Cell Immunol 1972; 5:180-9; PMID:4403471; http://dx.doi.org/10.1016/0008-8749(72)90094-9
5. Fagraeus A.The plasma cellular reaction and its relation to the formation of antibodies in vitro.J Immunol 1948; 58:1-13; PMID:18897986
6. Ron Y, De Baetselier P, Gordon J, Feldman M, Segal S.Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice.Eur J Immunol 1981; 11:964-8; PMID:6173237; http://dx.doi.org/10.1002/eji.1830111203
7. Ron Y, Sprent J.T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes.J Immunol 1987; 138:2848-56; PMID:2952725
8. Janeway CA Jr., Ron J, Katz ME.The B cell is the initiating antigen-presenting cell in peripheral lymph nodes.J Immunol 1987; 138:1051-5; PMID:3100626
9. Lanzavecchia A.Antigen-specific interaction between T and B cells.Nature 1985; 314:537-9; PMID:3157869; http://dx.doi.org/10.1038/314537a0
10. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, et al.CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.J Clin Invest 1997; 100:2757-65; PMID:9389740; http://dx.doi.org/10.1172/JCI119822
11. Vidard L, Kovacsovics-Bankowski M, Kraeft SK, Chen LB, Benacerraf B, Rock KL.Analysis of MHC class II presentation of particulate antigens of B lymphocytes.J Immunol 1996; 156:2809-18; PMID:8609400
12. Lanzavecchia A, Bove S.Specific B lymphocytes efficiently pick up, process and present antigen to T cells.Behring Inst Mitt 1985; 82-7; PMID:3002320
13. LeBien TW, Tedder TF.B lymphocytes: how they develop and function.Blood 2008; 112:1570-80; PMID:18725575; http://dx.doi.org/10.1182/blood-2008-02-078071
14. Lund FE, Garvy BA, Randall TD, Harris DP.Regulatory roles for cytokine-producing B cells in infection and autoimmune disease.Curr Dir Autoimmun 2005; 8:25-54; PMID:15564716; http://dx.doi.org/10.1159/000082086
15. Harris DP, Goodrich S, Mohrs K, Mohrs M, Lund FE.Cutting edge: the development of IL-4-producing B cells (B effector 2 cells) is controlled by IL-4, IL-4 receptor alpha, and Th2 cells.J Immunol 2005; 175:7103-7; PMID:16301612
16. Schultze JL, Michalak S, Lowne J, Wong A, Gilleece MH, Gribben JG, et al.Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses.J Exp Med 1999; 189:1-12; PMID:9874559; http://dx.doi.org/10.1084/jem.189.1.1
17. Küppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, et al.Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development.Proc Natl Acad Sci U S A 1994; 91:10962-6; PMID:7971992; http://dx.doi.org/10.1073/pnas.91.23.10962
18. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF.A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses.Immunity 2008; 28:639-50; PMID:18482568; http://dx.doi.org/10.1016/j.immuni.2008.03.017
19. Shimomura Y, Mizoguchi E, Sugimoto K, Kibe R, Benno Y, Mizoguchi A, et al.Regulatory role of B-1 B cells in chronic colitis.Int Immunol 2008; 20:729-37; PMID:18375938; http://dx.doi.org/10.1093/intimm/dxn031
20. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK.Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation.Immunity 2002; 16:219-30; PMID:11869683; http://dx.doi.org/10.1016/S1074-7613(02)00274-1
21. Brodt P, Gordon J.Natural resistance mechanisms may play a role in protection against chemical carcinogenesis.Cancer Immunol Immunother 1982; 13:125-7; PMID:6984356; http://dx.doi.org/10.1007/BF00205312
22. Monach PA, Schreiber H, Rowley DA.CD4+ and B lymphocytes in transplantation immunity.II.Augmented rejection of tumor allografts by mice lacking B cells.Transplantation 1993; 55:1356-61; PMID:8100090; http://dx.doi.org/10.1097/00007890-199306000-00027
23. Qin Z, Richter G, Schüler T, Ibe S, Cao X, Blankenstein T.B cells inhibit induction of T cell-dependent tumor immunity.Nat Med 1998; 4:627-30; PMID:9585241; http://dx.doi.org/10.1038/nm0598-627
24. Inoue S, Leitner WW, Golding B, Scott D.Inhibitory effects of B cells on antitumor immunity.Cancer Res 2006; 66:7741-7; PMID:16885377; http://dx.doi.org/10.1158/0008-5472.CAN-05-3766
25. Domschke C, Schuetz F, Ge Y, Seibel T, Falk C, Brors B, et al.Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis.Cancer Res 2009; 69:8420-8; PMID:19843863; http://dx.doi.org/10.1158/0008-5472.CAN-09-1627
26. Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, et al.B regulatory cells and the tumor-promoting actions of TNF-a during squamous carcinogenesis.Proc Natl Acad Sci U S A 2011; 108:10662-7; PMID:21670304; http://dx.doi.org/10.1073/pnas.1100994108
27. de Visser KE, Korets LV, Coussens LM.De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.Cancer Cell 2005; 7:411-23; PMID:15894262; http://dx.doi.org/10.1016/j.ccr.2005.04.014
28. Shah S, Divekar AA, Hilchey SP, Cho HM, Newman CL, Shin SU, et al.Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells.Int J Cancer 2005; 117:574-86; PMID:15912532; http://dx.doi.org/10.1002/ijc.21177
29. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M.B-cell-derived lymphotoxin promotes castration-resistant prostate cancer.Nature 2010; 464:302-5; PMID:20220849; http://dx.doi.org/10.1038/nature08782
30. DiLillo DJ, Yanaba K, Tedder TF.B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice.J Immunol 2010; 184:4006-16; PMID:20194720; http://dx.doi.org/10.4049/jimmunol.0903009
31. Domschke C, Schuetz F, Sommerfeldt N, Rom J, Scharf A, Sohn C, et al.Effects of distant metastasis and peripheral CA 15-3 on the induction of spontaneous T cell responses in breast cancer patients.Cancer Immunol Immunother 2010; 59:479-86; PMID:19957084; http://dx.doi.org/10.1007/s00262-009-0801-9
32. Mantovani A, Allavena P, Sica A, Balkwill F.Cancerrelated inflammation.Nature 2008; 454:436-44; PMID:18650914; http://dx.doi.org/10.1038/nature07205
33. Mantovani A.B cells and macrophages in cancer: yin and yang.Nat Med 2011; 17:285-6; PMID:21383737; http://dx.doi.org/10.1038/nm0311-285
34. Grivennikov SI, Greten FR, Karin M.Immunity, inflammation, and cancer.Cell 2010; 140:883-99; PMID:20303878; http://dx.doi.org/10.1016/j.cell.2010.01.025
35. Balkwill FR, Mantovani A.Cancer-related inflammation: common themes and therapeutic opportunities.Semin Cancer Biol 2012; 22:33-40; PMID:22210179; http://dx.doi.org/10.1016/j.semcancer.2011.12.005
36. Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M.Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta-and JNK1-dependent inflammation.Cancer Cell 2010; 17:89-97; PMID:20129250; http://dx.doi.org/10.1016/j.ccr.2009.12.008
37. Dougan M, Dranoff G.Immune therapy for cancer.Annu Rev Immunol 2009; 27:83-117; PMID:19007331; http://dx.doi.org/10.1146/annurev.immunol.021908.132544
38. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G.Immunological aspects of cancer chemotherapy.Nat Rev Immunol 2008; 8:59-73; PMID:18097448; http://dx.doi.org/10.1038/nri2216
39. Moshkani S, Kuzin II, Adewale F, Jansson J, Sanz I, Schwarz EM, et al.CD23+ CD21(high) CD1d(high) B cells in inflamed lymph nodes are a locally differentiated population with increased antigen capture and activation potential.J Immunol 2012; 188:5944-53; PMID:22593620; http://dx.doi.org/10.4049/jimmunol.1103071
40. DiLillo DJ, Horikawa M, Tedder TF.B-lymphocyte effector functions in health and disease.Immunol Res 2011; 49:281-92; PMID:21125343; http://dx.doi.org/10.1007/s12026-010-8189-3
41. Nimmerjahn F, Ravetch JV.Fcgamma receptors as regulators of immune responses.Nat Rev Immunol 2008; 8:34-47; PMID:18064051; http://dx.doi.org/10.1038/nri2206
42. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, et al.Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells.Cancer Res 2011; 71:3505-15; PMID:21444674; http://dx.doi.org/10.1158/0008-5472.CAN-10-4316
43. Zhang Y, Eliav Y, Shin SU, Schreiber TH, Podack ER, Tadmor T, et al.B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion.Cancer Immunol Immunother 2013; 62:87-99; PMID:22772949; http://dx.doi.org/10.1007/s00262-012-1313-6
44. Sorrentino R, Morello S, Forte G, Montinaro A, De Vita G, Luciano A, et al.B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma.Am J Respir Crit Care Med 2011; 183:1369-79; PMID:21278302; http://dx.doi.org/10.1164/rccm.201010-1738OC
45. João C, Ogle BM, Gay-Rabinstein C, Platt JL, Cascalho M.B cell-dependent TCR diversification.J Immunol 2004; 172:4709-16; PMID:15067046
46. Crowley MT, Reilly CR, Lo D.Influence of lymphocytes on the presence and organization of dendritic cell subsets in the spleen.J Immunol 1999; 163:4894-900; PMID:10528191
47. Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M.B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation.J Exp Med 2000; 192:475-82; PMID:10952717; http://dx.doi.org/10.1084/jem.192.4.475
48. Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, et al.Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers.Clin Cancer Res 2009; 15:4277-87; PMID:19549767; http://dx.doi.org/10.1158/1078-0432.CCR-09-0537
49. Barbera-Guillem E, Nelson MB, Barr B, Nyhus JK, May KF Jr., Feng L, et al.B lymphocyte pathology in human colorectal cancer.Experimental and clinical therapeutic effects of partial B cell depletion.Cancer Immunol Immunother 2000; 48:541-9; PMID:10630306; http://dx.doi.org/10.1007/PL00006672
50. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P.CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.Cancer Res 2003; 63:2836-43; PMID:12782589
51. Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al.CD19(+) CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.Immunity 2010; 32:129-40; PMID:20079667; http://dx.doi.org/10.1016/j.immuni.2009.11.009
52. Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R.Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.J Immunol 1998; 161:6977-84; PMID:9862733
53. Perricone MA, Smith KA, Claussen KA, Plog MS, Hempel DM, Roberts BL, et al.Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes.J Immunother 2004; 27:273-81; PMID:15235388; http://dx.doi.org/10.1097/00002371-200407000-00003
54. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, et al.Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.Blood 2002; 99:3319-25; PMID:11964299; http://dx.doi.org/10.1182/blood.V99.9.3319
55. Kondo E, Topp MS, Kiem HP, Obata Y, Morishima Y, Kuzushima K, et al.Efficient generation of antigenspecific cytotoxic T cells using retrovirally transduced CD40-activated B cells.J Immunol 2002; 169:2164-71; PMID:12165546
56. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH.RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy.Blood 2004; 103:2046-54; PMID:14630810; http://dx.doi.org/10.1182/blood-2003-07-2379
57. Van den Bosch GA, Ponsaerts P, Nijs G, Lenjou M, Vanham G, Van Bockstaele DR, et al.Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells.Clin Exp Immunol 2005; 139:458-67; PMID:15730391; http://dx.doi.org/10.1111/j.1365-2249.2005.02733.x
58. Chung Y, Kim BS, Kim YJ, Ko HJ, Ko SY, Kim DH, et al.CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo.Cancer Res 2006; 66:6843-50; PMID:16818662; http://dx.doi.org/10.1158/0008-5472.CAN-06-0889
59. Tamada K, Harada M, Okamoto T, Takenoyama M, Ito O, Matsuzaki G, et al.Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.Cancer Immunol Immunother 1995; 41:339-47; PMID:8635191; http://dx.doi.org/10.1007/BF01526553
60. Harada M, Okamoto T, Kurosawa S, Shinomiya Y, Ito O, Takenoyama M, et al.The antitumor activity induced by the in vivo administration of activated B cells bound to anti-CD3 monoclonal antibody.Cell Immunol 1995; 161:132-7; PMID:7867078; http://dx.doi.org/10.1006/cimm.1995.1017
61. Pretscher D, Distel LV, Grabenbauer GG, Wittlinger M, Buettner M, Niedobitek G.Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro-and hypopharyngeal carcinoma.BMC Cancer 2009; 9:292; PMID:19698134; http://dx.doi.org/10.1186/1471-2407-9-292
62. Ladányi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, et al.Prognostic impact of B-cell density in cutaneous melanoma.Cancer Immunol Immunother 2011; 60:1729-38; PMID:21779876; http://dx.doi.org/10.1007/s00262-011-1071-x
63. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, et al.CD20+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.Clin Cancer Res 2012; 18:3281-92; PMID:22553348; http://dx.doi.org/10.1158/1078-0432.CCR-12-0234
64. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, et al.A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin ? C as a compatible prognostic marker in human solid tumors.Clin Cancer Res 2012; 18:2695-703; PMID:22351685; http://dx.doi.org/10.1158/1078-0432.CCR-11-2210
65. Zirakzadeh AA, Marits P, Sherif A, Winqvist O.Multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies.J Immunol 2013; 190:5847-55; PMID:23630345; http://dx.doi.org/10.4049/jimmunol.1203279
66. Linnebacher M.Tumor-infiltrating B cells come into vogue.World J Gastroenterol 2013; 19:8-11; PMID:23326156; http://dx.doi.org/10.3748/wjg.v19.i1.8
67. Linnebacher M, Maletzki C.Tumor-infiltrating B cells: The ignored players in tumor immunology.Oncoimmunology 2012; 1:1186-8; PMID:23170274; http://dx.doi.org/10.4161/onci.20641
68. Nielsen JS, Nelson BH.Tumor-infiltrating B cells and T cells: Working together to promote patient survival.Oncoimmunology 2012; 1:1623-5; PMID:23264915; http://dx.doi.org/10.4161/onci.21650
69. Whiteside TL, Ferrone S.For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top.Clin Cancer Res 2012; 18:2417-9; PMID:22442060; http://dx.doi.org/10.1158/1078-0432.CCR-12-0566
70. Sakaguchi S.The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery.J Clin Invest 2003; 112:1310-2; PMID:14597756
71. Kuniyasu Y, Takahashi T, Itoh M, Shimizu J, Toda G, Sakaguchi S.Naturally anergic and suppressive CD25(+) CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation.Int Immunol 2000; 12:1145-55; PMID:10917889; http://dx.doi.org/10.1093/intimm/12.8.1145
72. Lim HW, Hillsamer P, Banham AH, Kim CH.Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells.J Immunol 2005; 175:4180-3; PMID:16177055
73. Kretschmer K, Apostolou I, Jaeckel E, Khazaie K, von Boehmer H.Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer.Immunol Rev 2006; 212:163-9; PMID:16903913; http://dx.doi.org/10.1111/j.0105-2896.2006.00411.x
74. Valzasina B, Piconese S, Guiducci C, Colombo MP.Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25-lymphocytes is thymus and proliferation independent.Cancer Res 2006; 66:4488-95; PMID:16618776; http://dx.doi.org/10.1158/0008-5472.CAN-05-4217
75. Wei B, Velazquez P, Turovskaya O, Spricher K, Aranda R, Kronenberg M, et al.Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets.Proc Natl Acad Sci U S A 2005; 102:2010-5; PMID:15684084; http://dx.doi.org/10.1073/pnas.0409449102
76. Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr.Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice.J Exp Med 1996; 184:2271-8; PMID:8976182; http://dx.doi.org/10.1084/jem.184.6.2271
77. Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S, et al.Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.J Rheumatol 2011; 38:633-41; PMID:21159836; http://dx.doi.org/10.3899/jrheum.100729
78. Kessel A, Haj T, Peri R, Snir A, Melamed D, Sabo E, et al.Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells.Autoimmun Rev 2012; 11:670-7; PMID:22155204; http://dx.doi.org/10.1016/j.autrev.2011.11.018
79. Reichardt P, Dornbach B, Rong S, Beissert S, Gueler F, Loser K, et al.Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse.Blood 2007; 110:1519-29; PMID:17392507; http://dx.doi.org/10.1182/blood-2006-10-053793
80. Chen X, Jensen PE.Cutting edge: primary B lymphocytes preferentially expand allogeneic FoxP3+ CD4 T cells.J Immunol 2007; 179:2046-50; PMID:17675460
81. Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL, et al.Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.Cancer Res 2009; 69:5996-6004; PMID:19567680; http://dx.doi.org/10.1158/0008-5472.CAN-08-4619
82. Tadmor T, Zhang Y, Cho HM, Podack ER, Rosenblatt JD.The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model.Cancer Immunol Immunother 2011; 60:609-19; PMID:21253724; http://dx.doi.org/10.1007/s00262-011-0972-z
83. Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, et al.Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.Cochrane Database Syst Rev 2012; 11:CD008079; PMID:23152253
84. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med 2002; 346:235-42; PMID:11807147; http://dx.doi.org/10.1056/NEJMoa011795
85. Cang S, Mukhi N, Wang K, Liu D.Novel CD20 monoclonal antibodies for lymphoma therapy.J Hematol Oncol 2012; 5:64; PMID:23057966; http://dx.doi.org/10.1186/1756-8722-5-64
86. Aklilu M, Stadler WM, Markiewicz M, Vogelzang NJ, Mahowald M, Johnson M, et al.Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma.Ann Oncol 2004; 15:1109-14; PMID:15205206; http://dx.doi.org/10.1093/annonc/mdh280
87. Hamaguchi Y, Uchida J, Cain DW, Venturi GM, Poe JC, Haas KM, et al.The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.J Immunol 2005; 174:4389-99; PMID:15778404
88. Haas KM, Poe JC, Steeber DA, Tedder TF.B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S.pneumoniae.Immunity 2005; 23:7-18; PMID:16039575; http://dx.doi.org/10.1016/j.immuni.2005.04.01
89. Schmidt M, Micke P, Gehrmann M, Hengstler JG.Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors.Oncoimmunology 2012; 1:1156-8; PMID:23170262; http://dx.doi.org/10.4161/onci.21653
90. Whiteside TL.Immune responses to cancer: are they potential biomarkers of prognosis?.Front Oncol 2013; 3:107; PMID:23730621; http://dx.doi.org/10.3389/fonc.2013.00107
91. Maletzki C, Jahnke A, Ostwald C, Klar E, Prall F, Linnebacher M.Ex-vivo clonally expanded B lymphocytes infiltrating colorectal carcinoma are of mature immunophenotype and produce functional IgG.PLoS One 2012; 7:e32639; PMID:22393427; http://dx.doi.org/10.1371/journal.pone.0032639
92. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al.Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.J Clin Oncol 2013; 31:88-94; PMID:23045577; http://dx.doi.org/10.1200/JCO.2012.42.7906
93. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, et al.Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.Cancer 2012; 118:63-71; PMID:21976132; http://dx.doi.org/10.1002/cncr.262